
































































































































































































































































































































































































































































































































































































































































































































223radium	 11.4	 <0.1	 	50kBq/kg	 Significantly	
increased	OS	
compared	with	
control	group	
(14.9	vs.	11.	3	
months);	
significantly	
longer	time	to	
first	skeletal	
event	(15.6	vs.	
9.8	months)		
Grade	3-4	anemia		in	13%	of	223Ra-
treated	patients	was	not	significantly	
different	from	placebo.	Gr	3-4	
thrombocytopenia	in	6%	of	treated	
patients	versus	2%	with	placebo.	
Occasional	cases	of	fatigue,	nausea	
and	loose	stools;	but	toxicities	in	
general	are	comparable	with	placebo.		
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In	the	ALSYMPCA	trial	in	men	with	CRPC	and	symptomatic	bone	metastases,	the	median	
age	of	patients	enrolled	was	71,	and	28%	were	aged	over	75	years.[48]	The	mean	
haemoglobin	level	of	patients	included	was	12.2g/dl,	which	seems	higher	than	expected	in	
routine	practice	for	this	patient	population;	and	no	data	are	given	about	comorbidities	or	
geriatric	functional	assessment.		
It	is	not	clear	how	many	of	the	patients	who	did	not	have	prior	docetaxel	had	refused	
chemotherapy,	how	many	were	judged	unfit	for	chemotherapy,	and	how	many	had	no	
access	to	it.	It	is	therefore	difficult	to	judge	the	efficacy	and	safety	of	this	treatment	in	
elderly	patients.	In	the	poorer	PS	group,	the	0.73	HR	for	OS	was	in	the	same	positive	
direction	as	for	the	population	as	a	whole.	However,	the	benefit	of	treatment	did	not	
achieve	statistical	significance;	and,	as	with	any	subgroup	analysis,	this	finding	can	be	
considered	only	as	hypothesis	generating.	
	
Protection	and	safety	when	using	therapeutic	radiopharmaceuticals	
Protecting	hospital	staff,	the	general	public	and	the	environment	from	unnecessary	
exposure	to	radiation	is	a	major	concern	in	radiopharmaceutical	diagnostics	and	therapy.	
Relevant	regulations	differ	considerably	from	one	country	to	another.	For	example,	there	
have	been	concerns	in	Germany	about	the	possibility	of	exhaled	radon.	Swiss	patients	given	
223Ra	have	to	accept	that	cremation	must	be	postponed	(or	burial	used	instead)	if	they	die	
within	seven	days	of	its	administration.	Nuclear	medicine	physicians	and	technicians	need	
to	check	which	are	applicable	to	the	place	they	practice.	
Elderly	patients	are	more	likely	than	their	younger	counterparts	to	require	urgent	surgery	
for	conditions	unrelated	to	cancer.	In	any	patient	with	bone	metastases,	there	is	the	
possibility	that	fracture	or	spinal	cord	compression	will	necessitate	surgical	intervention.	
More	generally,	a	patient’s	overall	functional	status	–	especially	possible	incontinence	–	is	
an	age-related	factor	that	is	clearly	relevant	to	radioprotection.		
Appropriate	radioprotection	advice	should	be	available	to	hospital	staff	when	required	in	
managing	a	patient	recently	treated	with	a	radiopharmaceutical	(protective	eyeware	for	
operating	theatre	staff	and	double	pairs	of	gloves,	for	example,	would	be	appropriate).	
	
Discussion	and	conclusions	
The	use	of	radiopharmaceuticals	to	accurately	image	the	spread	of	disease	is	of	proven	
value.	They	are	also	likely	to	be	useful	in	quantifying	the	burden	of	metabolically	active	
tumour,	which	will	further	aid	in	personalising	treatment.	In	relation	to	the	elderly	patient	
with	significant	comorbidities	and	limited	life	expectancy,	the	prognostic	information	such	
imaging	could	provide	would	be	particularly	valuable	in	enabling	them	to	avoid	
unnecessary	treatment	and	preserve	quality	of	life.		
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When	attempting	to	make	recommendations	for	the	elderly,	it	is	striking	to	find	that	so	few	
older	patients	have	been	entered	into	pivotal	clinical	trials,	even	of	targeted	anti-cancer	
agents.[61]	In	an	ideal	world,	the	proportion	of	elderly	patients	included	in	a	trial	would	
match	the	proportion	of	those	with	the	disease.	In	the	real	world,	there	may	be	a	case	for	
providing	companies	with	incentives	to	enrol	such	patients	in	key	studies,	or	with	requiring	
them	to	conduct	trials	specifically	in	the	elderly,	those	who	have	comorbidities	and	those	
who	are	frailer.[62]		
The	fifty-year	history	of	131I	in	thyroid	tumours	should	give	us	confidence	that	
radiopharmaceuticals	can	safely	be	used	in	the	treatment	of	cancer	in	a	wide	range	of	
patients.	However,	with	each	new	radioisotope	and	indication	come	unquantified	risks.	
This	applies	both	to	the	patients	treated	and	to	the	staff	treating	them.	In	the	elderly	
prostate	cancer	patient	with	symptomatic	bone	metastases	and	a	life	expectancy	of	under	
five	years,	it	is	very	unlikely	that	long-term	effects	of	radiation	exposure	will	become	
apparent.	In	a	young	woman	with	breast	cancer,	this	is	not	necessarily	the	case.	However,	
both	kinds	of	patient	must	be	assessed	for	the	risk	of	short-term	toxic	effects,	for	example	
to	bone	marrow	or	the	kidney.	And	staff	administering	radiopharmaceuticals	are	
understandably	concerned	about	the	potential	long-term	impact	of	radiation	on	their	
general	health	and	wellbeing,	including	fertility.	Both	patients	and	staff	should	be	fully	
informed	and	given	written	information	about	risks.		
Bone-seeking	radiopharmaceuticals	have	no	role	in	preventing	the	development	of	visceral	
metastases.	While	the	risk	of	such	involvement	is	initially	low	in	prostate	cancer,	almost	
50%	of	patients	develop	them	at	later	stages	of	disease,	and,	with	the	prolongation	of	
survival	following	the	introduction	of	new	drugs,	this	proportion	is	likely	to	increase.	[63]	
Studies	to	assess	whether	the	use	or	radiopharmaceuticals	in	combination	with	chemo-	and	
other	systemic	therapies	will	increase	clinical	benefit	with	acceptable	additional	toxicity	are	
now	being	conducted.		
Since	the	relative	costs	of	individual	agents	vary	greatly	from	one	health	system	and	
country	to	another,	it	is	difficult	to	include	such	factors	in	clinical	recommendations.	
However,	the	availability	and	expense	of	different	agents	are	clearly	relevant	to	the	making	
of	therapeutic	decisions	in	the	everyday	management	of	the	elderly,	as	with	all	cancer	
patients.	
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Table	4			Take-home	messages	
• Include	more	elderly	patients	in	pivotal	clinical	trials;	this	applies	also	to	targeted	
anti-cancer	agents	
The	under-representation	of	elderly	cancer	patients	in	pivotal	clinical	trials	restricts	
our	ability	to	tailor	management	to	their	specific	circumstances	(comorbidities	and	
fraility)	
• Diagnostic	radiopharmaceuticals	are	not	an	issue	of	particular	concern	in	elderly	
patients,	even	in	the	presence	of	vulnerability	
Consider	increasing	isotope	dose	activity	to	decrease	scan	time	and	so	minimize	
patient	discomfort	
• Therapeutic	radiopharmaceuticals	in	elderly	patients	with	hormone-resistant	
prostate	cancer	and	symptomatic	metastases	are	safe	but	require	
o assessment	of	short-term	toxic	effects	on	bone	marrow	and		
o adequate	information	to	be	given	to	patients,	family	members	
and	care	staff	
• More	studies	are	needed	on	the	combination	of	therapeutic	radiopharmaceuticals	
with	chemo-	and/or	other	systemic	therapies	to	determine	if	increased	clinical	
benefit	can	be	achieved	with	acceptable	additional	toxicity	
	
	
Acknowledgements	
Rob	Stepney	PhD	(medical	writer,	Charlbury,	UK)	was	rapporteur	at	the	Paris	meeting	of	
the	Task	Force,	prepared	the	first	draft	of	this	paper,	and	helped	in	the	editing	of	
subsequent	drafts.	We	also	gratefully	acknowledge	the	following	for	their	helpful	
comments:	Axel	Heidenreich,	Bertrand	Tombal,	Peter	Mulders,	and	Gouri	Shankar	
Bhattacharyya.	
	
22	
References	
[1]	Pysz	MA,	Gambhir	SS,	Willmann	JK.	Molecular	imaging:	current	status	and	emerging	
strategies.	Clinical	Radiology	2010;65:500-16.	
[2]	Wildiers	H,	Heeren	P,	Puts	M	et	al.	International	Society	of	Geriatric	Oncology	consensus	
on	geriatric	assessment	in	older	patients	with	cancer.	J	Clin	Oncol	2014;20:2595-603.		
[3]	Droz	J-P,	Albrand	G,	Gillesen	S	et	al.	Management	of	prostate	cancer	in	elderly	patients:		
recommendations	of	a	Task	Force	of	the	International	Society	of	Geriatric	Oncology	(SIOG).	
Eur	Urol	2017	in	press		
[4]	http://seer.cancer.gov/statfacts/html/breast.html	accessed	19.1.15	
[5]	Rubini	G,	Nicoletti	A,	Rubini	D,	Asabella	AN.	Radiometabolic	treatment	of	bone-
metastasizing	cancer:	from	186rhenium	to	223radium.	Cancer	Biother	Radiopharm	
2014;29:1-11.		
[6]	Frieling	JS,	Basanta	D,	Lynch	CC.	Current	and	emerging	therapies	for	bone	mestastatic	
castrate-resistant	prostate	cancer.	Cancer	Control	2015;22:109-20.	
[7]	Fried,	J	Gerontol	Biol	Sci	2004.	Bergman	H,	Ferrucci	L,	Guralnik	J	et	al:	Frailty:	an	
emerging	research	and	clinical	paradigm	–	issues	and	controversies.	J	Gerontol	A	Biol	Sci	
Med	Sci	2007;62:731-7.	
[8]	Hurria	A,	Togawa	K,	Mohile	SG	et	al.	Predicting	chemotherapy	toxicity	in	older	adults	
with	cancer:	a	prospective	multicenter	study.	J	Clin	Oncol	2011;29:3457-65.	
[9]	Extermann	M,	Boler	I,	Reich	RR	et	al.	Predicting	the	risk	of	chemotherapy	toxicity	in	
older	patients:	the	Chemotherapy	Risk	Assessment	Scale	for	High-Age	Patients	(CRASH)	
score.	Cancer	2012;	118:3377-86.	
[10]	D’Amico	AV,	Chen	MH,	Renshaw	AA	et	al.	Androgen	suppression	and	radiation	vs	
radiation	alone	for	prostate	cancer:	a	randomized	trial.	JAMA	2008;	299:	289-295.	
[11]	Hillner	BE,	Siegel	BA,	Liu	D	et	al.	Impact	of	positron	emission	tomography/computed	
tomography	and	positron	emission	tomography	(PET)	alone	on	expected	management	of	
patients	with	cancer:	initial	results	from	the	National	Oncologic	PET	Registry.	J	Clin	Oncol	
2008;	26:2155-61.	
[12]	Santos-Oliveira	R.Undesirable	events	with	radiopharmaceuticals.	Tohoku	J	Exp	Med.	
2009;	217:	251-257.		
[13]	Codreanu	I,	Dasanu	CA,	Weinstein	GS,	Divgi	C.	Fluorodeoxyglucose-induced	allergic	
reaction:	A	case	report.	J	Oncol	Pharm	Pract	2013	19:	86-88.		
[14]	Lee	DY,	Lee	JJ,	Kwon	HS	et	al.	An	unusual	case	of	anaphylaxis	after	fluorine-18-labeled	
fluorodeoxyglucose	injection.Nucl	Med	Mol	Imaging.	2013;47:	201-204.		
23	
[15]	Silberstein	EB.	Prevalence	of	adverse	reactions	to	positron	emitting	
radiopharmaceuticals	in	nuclear	medicine.	Pharmacopeia	Committee	of	the	Society	of	
Nuclear	Medicine.	J	Nucl	Med	1998;	39:	2190-2192.	
[16]	Silberstein	EB,	Ryan	J.	Prevalence	of	adverse	reactions	in	nuclear	medicine.	
Pharmacopeia	Committee	of	the	Society	of	Nuclear	Medicine.	J	Nucl	Med	1996;	37:	185-
192.	
[17]	Goyal	J,	Antonarakis	ES.	Bone	targeting	radiopharmaceuticals	for	the	treatment	of	
prostate	cancer	with	bone	metastases.	Cancer	Lett	2012;	323:135-46.	
[18]	Scher	I,	Morris	MJ	Stadler	NM	et	al.	Trial	design	and	objectives	for	castration-resistant	
prostate	cancer:	update	recommendations	from	the	prostate	cancer	clinical	trials	working	
group	3.	J	Clin	Oncol	2016;34:1402-18.	
[19]	Hsu	HH,	Ko	KH,	Chou	YC	et	al.	SUVmax	and	tumor	size	predict	surgical	outcome	of	
synchronous	multiple	primary	lung	cancers.	Medicine	Baltimore	2016	epub	2016	
Feb;95(6):e2351.	doi:	10.1097/MD.0000000000002351.	
[20]	Machtay	M,	Duan	F,	Siegel	BA	et	al.	Prediction	of	survival	by	[18F]Fluorodeoxyglucose	
Positron	Emission	Tomography	in	patients	with	locally	advanced	non-small-cell	lung	cancer	
undergoing	definitive	chemoradiation	therapy:	Results	of	the	ACRIN	6668/RTOG	0235	Trial.	
J	Clin	Oncol	2013;31:3823-30.	
[21]	Hasenclever	D,	Kurch	L,	Mauz-Körholz	et	al.	qPET	-	a	quantitative	extension	of	the	
Deauville	scale	to	assess	response	in	interim	FDG-PET	scans	in	lymphoma.	Eur	J	Nucl	Med	
Mol	Imaging.	2014;41:1301-8.	
[22]	Senft	A,	de	Bree	R,	Hoekstra	OS	et	al.	Screening	for	distant	metastases	in	head	and	
neck	cancer	patients	by	chest	CT	or	whole	body	FDG-PET:	a	prospective	multicenter	trial.	
Radiother	Oncol	2008.	87:	221-9.		
[23]	Weber	WA,	Ott	K,	Becker	K	et	al.	Prediction	of	response	to	preoperative	chemotherapy	
in	adenocarcinomas	of	the	oesophagogastric	junction	by	metabolic	imaging.	J	Clin	Oncol	
2001;	19:	3058–3065.		
	[24]	Ott	K,	Fink	U,	Becker	K	et	al.	Prediction	of	response	to	preoperative	chemotherapy	in	
gastric	carcinoma	by	metabolic	imaging:	results	of	a	prospective	trial.	J	Clin	Oncol	2003;	21:	
4604–4610.		
[25]	Benz	MR,	Czernin	J,	Allen-Auerbach	MS,	et	al.	FDG	PET/CT	imaging	predicts	
histopathologic	treatment	responses	after	the	initial	cycle	of	neoadjuvant	chemotherapy	in	
high-grade	soft-tissue	sarcomas.	Clin	Cancer	Res	2009;	15:	2856–63.		
	[26]	Gavid	M,et	al.	[18F]-FDG	PET-CT	prediction	of	response	to	induction	chemotherapy	in	
head	and	neck	squamous	cell	carcinoma:	Preliminary	findings.	European	Annals	of	
Otorhinolaryngology,	Head	and	Neck	diseases	(2014),	
http://dx.doi.org/10.1016/j.anorl.2014.01.009		
24	
[27]	Adkins	D,	Ley	J,	Dehdashti	F,	Siegel	MJ	et	al.	A	prospective	trial	comparing	FDG-PET/CT	
and	CT	to	assess	tumor	response	to	cetuximab	in	patients	with	incurable	squamous	cell	
carcinoma	of	the	head	and	neck.	Cancer	Med	2014	;3:1493-1501.	
[28]	Minamimoto	R,	Fayad	L,	Advani	R	et	al.	Diffuse	large	B-cell	lymphoma:	prospective	
multicenter	comparison	of	early	interim	FLT	PET/CT	versus	FDG	PET/CT	with	IHP,	EORTC,	
Deauville,	and	PERCIST	criteria	for	early	therapeutic	monitoring.	Radiology	2016;	280:220-
9.			
[29]	Schöder	H,	Zelenetz	AD,	Hamlin	P	et	al.	Prospective	study	of	3'-Deoxy-3'-18F-
Fluorothymidine	PET	for	early	interim	response	assessment	in	advanced-stage	B-cell	
lymphoma.	J	Nucl	Med	2016;	57:728-34	
[30]	MacManus	MP,	Hicks	RJ.	The	role	of	positron	emission	tomography/	computed	
tomography	in	radiation	therapy	planning.	Sem	Nuclear	Med	2012;	42:	308-319		
[31]	Parker	C,	Gillessen	S,	Heidenreich	A,	Horwich	A	on	behalf	of	the	ESMO	Guidelines	
Committee.	Cancer	of	the	prostate:	ESMO	Clinical	Practice	Guidelines	for	diagnosis,	
treatment	and	follow-up.	Ann	Oncol	2015;	26:	suppl	5	v69-v77.		
[32]	Apolo	AB,	Lindenberg	L,	Shih	JH	et	al.	Prospective	study	evaluating	Na18F-Positron	
Emission	Tomography-Computed	Tomography	(NAF-PET/CT)	in	predicting	clinical	outcomes	
and	survival	in	advanced	prostate	cancer.	J	Nucl	Med	2016	Jan	21	pii:jnumed.115.166512	
[33]	Evangelista	L,	Briganti	A,	Fanti	S	et	al.	New	clinical	indications	for	18F/11C	choline,	new	
tracers	for	positron	emission	tomography	and	a	promising	hybrid	device	for	prostate	
cancer	staging:	a	systematic	review	of	the	literature.	Eur	Urol	2016	
[34]	Maurer	T,	Eiber	M,	Schwaiger	M,	Gschwend		JE.	Current	use	of	PMSA-PET	in	prostate	
cancer	management.	Nat	Rev	Urol	2016;13:226-35.	
[35]	Ahmadzadehfar	H,	Azgoni	K,	Hauser	S	et	al.	68Ga-PSMA-11	as	a	gatekeeper	for	the	
treatment	of	metastatic	prostate	cancer	with	radium-223:	proof	of	concept.	J	Nucl	Med	
2016	DOI:	10.2967/jnumed.116.178533			
[36]	Tenhunen	M,	Lehtonen	S,	Heikkonen	J	et	al.	First-day	iodine	kinetics	is	useful	for	
individualizing	radiation	safety	precautions	for	thyroid	carcinoma	patients.	Nucl	Med	
Commun	2013;34:1208-15.	
[37]	Rao	AV,	Akabani	G,	Rizzieri	DA.	Radioimmunotherapy	for	Non-Hodgkin’s	Lymphoma.	
Clin	Med	Res	2005;3:157-65.	
[38]	Sangro	B,	Carpanese	L,	Cianni	R	et	al.	Survival	after	yttrium-90	resin	microsphere	
radioembolization	of	hepatocellular	carcinoma	across	Barcelona	Clinic	liver	cancer	stages:	a	
European	evaluation.	Hepatology	2011;54:	
[39]		Orlando	A,	Leandro	G,	Olivo	M,	Andriulli	A,	Cottone	M.	Radiofrequency	thermal	
ablation	vs	percutaneous	ethanol	injection	for	small	hepatocellular	carcinoma	in	cirrhosis.	
Meta-analysis	of	randomized	controlled	trials.	Am	J	Gastroenterol	2009;104:514-24.		
25	
[40]	Gaba	RC,	Lewandowski	RJ,	Kulik	LM	et	al.	Radiation	lobectomy.	preliminary	findings	of	
hepatic	volumetric	response	to	lobar	yttrium-90	radioembolization.	Ann	Surg	Oncol	
2009;16:1587-96.	
[41]	Salem	R,	Thurston	KG:	Radioembolization	with	(90)yttrium	microspheres.	a	state-of-
the-art	brachytherapy	treatment	for	primary	and	secondary	liver	malignancies,	Part	1	
technical	and	methodologic	considerations.	J	Vasc	Interv	Radiol	2006;17:1251-78.	
[42]	Kwekkeboom	DJ,	de	Herder	WW,	Kam	BL	et	al.Treatment	with	the	radiolabeled	
somatostatin	analog	[177	Lu-DOTA	0,Tyr3]octreotate:	toxicity,	efficacy,	and	survival.	J	Clin	
Oncol.	2008;26:2124-2130.		
[43]	Vinjamuri	S,	Gilbert	TM,	Banks	M	et	al.	Peptide	radionuclide	therapy	with	(90)Y-
DOTATATE/(90)Y-DOTATOC	in	patients	with	progressive	metastatic	neuroendocrine	
tumours:	assessment	of	response,	survival	and	toxicity.	Br	J	Cancer	2013;	108:	1440-1448.	
[44]	Florimente	L,	Dallavedova	L,	Maffioli	LS.	Radium-223	dichloride	in	clinical	practice:	a	
review.	Eur	J	Nucl	Med	Mol	Imaging	2016;	43:	1896-1909.	
[45]	Nilsson	S,	Cislo	P,	Sartor	O	et	al.	Patient-reported	quality	of	life	analysis	of	radium-223	
dichloride	from	the	phase	III	ALSYMPCA	study.	Ann	Oncol	2016;	27:	868-874.	
[46]	James	N,	Pirrie	S,	Pope	A	et	al.	TRAPEZE:	a	randomized	controlled	trial	of	the	clinical	
effectiveness	and	cost-effectiveness	of	chemotherapy	with	zoledronic	acid,	strontium-89,	
or	both,	in	men	with	bony	metastatic	castration	refractory	prostate	cancer.	Health	Technol	
Assess	2016;	20:		
[47]	NCCN	Clinical	Practice	Guidelines	in	Oncology:	Myeloid	Growth	Factors.	v2.2014	
[48]	Parker	C,	Nilsson	S,	Heinrich	D	et	al.	Alpha	emitter	radium-223	and	survival	in	
metastatic	prostate	cancer.	N	Engl	J	Med	2013;	369;213-23.	
[49]	Berthold	DR,	Pond	GR,	Soban	F	et	al.	Docetaxel	plus	prednisone	or	mitoxantrone	plus	
prednisone	for	advanced	prostate	cancer:	updated	survival	in	the	TAX	327	study.	J	Clin	
Oncol	2008;	26:242-5.	
[50]	Beer	TM,	Armstrong	AJ,	Rathkopf	DE	et	al.	Enzalutamide	in	metastatic	prostate	cancer	
before	chemotherapy.	N	Engl	J	Med	2014;	371:	424-33.		
[51]	Kantoff	W,	Higano	CS,	Shore	ND	et	al.	Sipuleucel-T	immunotherapy	for	castration-
resistant	prostate	cancer.	N	Engl	J	Med	2010;	363:	411-22.		
[52]	Ryan	CJ,	Smith	MR,	de	Bono	JS	et	al.	Abiraterone	in	metastatic	prostate	cancer	without	
previous	chemotherapy.	N	Engl	J	Med	2013;	368:	138-48.		
[53]	Ryan	C,	Smith	MR,	Fizazi	K	et	al.	Abiraterone	acetate	plus	prednisone	versus	placebo	
plus	prednisone	in	chemotherapy-naive	men	with	metastatic	castration-resistant	prostate	
cancer	(COU-AA-302):	final	overall	survival	analysis	of	a	randomised,	double-blind,	placebo-
controlled	phase	3	study.	Lancet	Oncol	2015;16:	152-60.	
26	
[54]	Mottet	N,	Bellmunt	J,	Briers	E	et	al.	EAU-ESTRO-SIOG	Guidelines	on	Prostate	Cancer.	
European	Association	of	Urology	2016.	
[55]	Droz	JP,	Aapro	M,	Balducci	L	et	al.	Management	of	prostate	cancer	in	senior	adults:	
updated	recommendations	of	a	working	group	of	the	International	Society	of	Geriatric	
Oncology	(SIOG).	Lancet	Oncol	2014;	15:	e404-414.	 	
[56]	NCCN	Clinical	Practice	Guidelines	in	Oncology:	Prostate	Cancer	v2.2016	
[57]	American	Urological	Association.	Castration-Resistant	Prostate	Cancer:	AUA	Guideline.	
As	amended	March	2015		 	
[58]	Basch	E,	Loblaw	A,	Oliver	TK	et	al.	Systemic	therapy	in	men	with	metastatic	castrate-
resistant	prostate	cancer:	American	Society	of	Clinical	Oncology	and	Cancer	Care	Ontario	
Clinical	Practice	Guidelines.	J	Clin	Oncol	2014;	32:	3436-3448.	
[59]	Berthold	DR,	Pond	GR,	Soban	F	et	al.	Docetaxel	plus	prednisone	or	mitoxantrone	plus	
prednisone	for	advanced	prostate	cancer:	updated	survival	in	the	TAX	327	study.	J	Clin	
Oncol	2008;	26:	242-245.	
[60]		Beer	TM,	Armstrong	AJ,	Rathkopf	DE	et	al.	Enzalutamide	in	metastatic	prostate	cancer	
patients	before	chemotherapy.	New	Engl	J	Med	2014;	371:	424-433.		
[61]		Kelly	CM,	Power	DG,	Lichtman	SM.	Targeted	therapy	in	older	patients	with	solid	
tumors.	J	Clin	Oncol	2014;	
[62]	Hurria	A,	Dale	W,	Mooney	M	et	al.	Designing	therapeutic	clinical	trials	for	older	and	
frail	adults	with	cancer:U13	conference	recommendations.	J	Clin	Oncol	2014;	32:	2587-
2594.	
[63]	Pezaro	CJ,	Omlin	A,	Lorente	D	et	al.	Visceral	disease	in	castration-resistant	prostate	
cancer.	Eur	Urol	2014;	65:	270-273.	
	
